EL 1803
Alternative Names: EL-1803Latest Information Update: 20 Jul 2022
At a glance
- Originator Elyson Pharm
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cardiovascular disorders
Most Recent Events
- 11 Jul 2022 Preclinical trials in Cardiovascular disorders in South Korea (unspecified) (Elyson Pharmaceuticals pipeline, July 2022)